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Molecular dockingAbstract A series of N-(2-(4-chlorobenzyl)benzo[d]oxazol-5-yl)-3-substituted-propanamide
(3a–3n) were synthesized and evaluated for their acute and chronic anti-inﬂammatory potential.
The structure of the compounds was elucidated by elemental and spectral (IR, 1H NMR and
MS) analysis. The synthesized compounds (at a dose of 20 mg/kg b.wt. p.o.) have shown their abil-
ity to provide 45.1–81.7% protection against carrageenan-induced paw edema, in comparison with
diclofenac sodium (69.5%) and ibuprofen (64.7%). The most active compounds 3a, 3l and 3n were
screened for chronic anti-inﬂammatory activity (cotton-pellet-induced granuloma) and to study
their ulcerogenic activity. Compounds 3a, 3l and 3n showed 48.4%, 39.3% and 44.0% protection
against cotton pellets-induced granuloma compared to diclofenac sodium (60.2%). The tested com-
pounds were less ulcerogenic than the ibuprofen. Molecular modeling studies suggest that these
compounds have strong interaction with the COX-2 enzyme, which is responsible for the activity.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-steroidal anti-inﬂammatory drugs are among the most
widely used of all therapeutic agents. These drugs are often
taken without prescription for minor aches and pains.
Several anti-inﬂammatory agents are available in the market
and none of these is ideal in controlling or modifying the signs
and symptoms of inﬂammation. Gastrointestinal bleeding,
ulceration and complications are the main complications of
these drugs; therefore the emphasis on minimizing these risks
has been one of the greatest challenges to develop much safer
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related to amide and heterocyclic compounds, the substituted
benzo[d]oxazoles have attracted much attention due to their
utilization as analgesic and anti-inﬂammatory (Pilli et al.,
1994; Gokhan et al., 1996; Paramashivappa et al., 2003;
Sondhi et al., 2006; Seth et al., 2014), antifungal (Vinsova
et al., 2006; Kim et al., 2010), anti-bacterial (Yildiz-Oren
et al., 2004; Gadegoni et al., 2013), anti-tubercular agent
(Arisoy et al., 2013) and in Alzheimer’s disease (Chun et al.,
2008). These activities probably result from its planar and
compact structure. All anti-inﬂammatory agents act by the
inhibition of the cyclooxygenase (COX) enzyme. There are
two isoforms of cyclooxygenase enzyme; COX-1, which is
found primarily in blood vessels, kidney and stomach, and
COX-2, which is responsible for induction of inﬂammation.
All, over-the-counter anti-inﬂammatory agents inhibit both
COX-1 and COX-2 at varying degrees. COX-1 has short bind-
ing site, while COX-2 enzyme has long binding active site. The
anti-inﬂammatory and analgesic properties of NSAIDs are
derived from COX-2 inhibition and the common side effect
such as gastrointestinal bleeding is due to inhibition of
COX-1.
The molecular docking approach is one of the most rational
and authentic approaches in the drug design and discovery for
studying the molecular interaction of small molecules. The
docking involves two main components such as search algo-
rithm and the scoring functions. The search algorithm involves
the positioning of the molecular conformations in the active
site while the scoring function determines the most energeti-
cally favorable orientation of the molecule. Based on the
reported studies and the substantial need for superior anti-in-
ﬂammatory activity we have designed the hybrid compounds
of benzo[d]oxazole containing ACONHCH2CH2AN, which
can interact with the possible binding site (Tyr-355, Arg-120)
of the COX-2 enzyme. Molecular modeling studies were per-
formed in order to prove whether COX-2 was a possible target
for the synthesized compounds or not. With this theory, we are
reporting the synthesis, characterization and biological evalua-
tion of title compounds for their acute and chronic anti-in-
ﬂammatory activity as well as their ulcerogenic potential. In
this study we have used Autodock 4.2 (Morris et al., 2009)
for docking of the synthesized compounds on COX-2 crystal
structure (PDB: 3NT1) with (Duggan et al., 2010) binding site
which was also previously reported by many authors
(Raghavendra et al., 2011, 2013; Basile et al., 2012)
Additionally we also have calculated and compared the bind-
ing afﬁnities of these compounds with standard reference
molecules.
2. Material and methods
2.1. Chemistry
Nuclear magnetic resonance spectra (NMR) were recorded on
Bruker, Avance DPX-300 spectrometer (300 MHz) using
CDCl3. Chemical shifts are reported in ppm related to tetram-
ethylsilane (TMS) as the internal standard. Infrared (IR) spec-
tra were recorded in potassium bromide (Merck, Darmstadt,
Germany) disks, using Perkin Elmer IR spectrophotometer.
Melting points (mp) were recorded using Stuart Scientiﬁc
electro-thermal melting point apparatus (UK), and areuncorrected. Mass spectra were recorded on a LC-MS-LCQ
(Agilent, Advantage-Max) instrument equipped with electro-
spray ion (ESI) source and elemental analyses were carried
out on a Heraeus Carlo Erba-1108 elemental analyzer. Purity
of the compounds and progress of the reaction were monitored
using TLC and compounds were puriﬁed using column chro-
matography. Starting material, reagents and solvents were
purchased from Sigma Aldrich Chemical Co., USA, and
Himedia (Mumbai, India) and were used without further
puriﬁcation.
2.2. Synthesis
2.2.1. The title compounds were prepared using the synthetic
strategy described in Scheme 1. Compound 5-amino-2-(4-
chloro benzyl)-benzo[d]oxazole (1) was acetylated with
chloropropionyl chloride in dry benzene. The second reaction
was carried out by reﬂuxing 3-chloro-N-(2-(4-chloro-benzyl)-
benzo-[d]oxazol-5-yl)-propionamide (2) with different sec-
ondary amine or heterocyclic compound in dry condition for
6 hours to give ﬁnal compounds in variable yield between
30% and 70%.
2.3. Pharmacological evaluation
2.3.1. Animals
The animals were procured from the Animal House Center,
Faculty of Pharmacy, and were divided and housed in different
cages at 25 ± 2 C, relative humidity of 50–65%, under 12 h
light and dark cycles; they were fed standard animal feed.
All animals were acclimatized for a week before use. All the
experiments were conducted after receiving the approval from
University Animal Ethics Committee. The acute anti-in-
ﬂammatory activity of the compounds was evaluated on
Wister rats as described by Winter et al. (1962) while chronic
anti-inﬂammatory activity of a few compounds was studied
according to the cotton pellet granuloma method of D’arcy
et al. (1960). The ulcerogenic activity of compounds (3a, 3l
and 3n; 60 mg/kg b.wt.) and ibuprofen (60 mg/kg b.wt.) was
performed according to Cioli et al. (1979).
2.3.2. Acute anti-inﬂammatory activity
The animals (albino rats) were divided into groups of four.
Synthesized compounds were given orally (20 mg/kg b.wt.)
and the paw volume was determined plethysmographically
(Ugo-Basel, Italy). The control group received equivalent vol-
ume of normal saline. The reference group received ibuprofen
(20 mg/kg b.wt. p.o.). After half an hour the carrageenan
(0.1 mL of 1.0% w/v solution) in sterile saline was injected into
the subplantar tissue of the rat’s right hind paw. The paw vol-
ume was determined at hourly intervals for 3 h (0, 1, 2, 3 h).
The percent of inhibition of inﬂammation was determined
using the following formula: % inhibition = 100 · (1  Vs/
Vc), where ‘Vc’ represents edema volume in control and ‘Vs’
edema volume in the group treated with sample.2.3.3. Cotton pellets induced granuloma
Sterile cotton-pellets (10 mg each) were implanted sub-
cutaneously in the back axilla regions of each rat under keta-
mine hydrochloride (100 mg/kg i.m.) anesthesia. The animals
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3a=dimethylamino; 3b=diethylamino; 3c=dipropylamino; 3d= N-cyclohexyl-N-
methyl-amino; 3e=dicyclohexylamino; 3f =1-piperidinyl; 3g= 4-methyl-1-
piperidinyl; 3h=2-methyl-1-piperidinyl; 3i=4-ethyl-1-piperazinyl; 3j=4-phenyl-1-
piperazinyl; 3k=4-fluorophenyl-1-piperazinyl; 3l=4-(2,3-dichlorophenyl-1-
piperazinyl; 3m= 4-((benzo[d][1,3]dioxol-6-yl)-methyl)-piperazin-1-yl; 3n=4(4-
nitrophenyl)-1-piperazinyl.(3a-3n)
(2)
R=
Scheme 1 Synthesis of benzo[d]oxazole derivatives 3a–3n. Reagent and conditions: (a) PPA, 2 h, 80 C; (b) chloropropionyl chloride, dry
benzene; (c) different secondary amines, benzene, reﬂux.
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pounds (3a, 3l or 3n; 20 mg/kg) for 7 consecutive days, while
the control group received normal saline (vehicle control).
The diclofenac sodium was used as reference drug (10 mg/kg
body weight). Scariﬁcation was made after 8th day and the
cotton-pellets were removed, freed from extraneous tissues.
The wet pellets were weighed and then dried in a vacuum oven
at 60 C for 4 h to a constant weight; after that the dried pellets
were weighed again. Increment in the dry weight of the pellets
was taken as a measure of granuloma formation.
2.3.4. Acute ulcerogenic activity
Wistar rats (150–200 g) were used in the present experiment.
Three times the anti-inﬂammatory dose of standard/com-
pounds was used. Rats (n= 5) were divided into different
groups. Compounds (60 mg/kg b.wt.) or ibuprofen (60 mg/kg
b.wt.) was given orally. Control group received only normal
saline. The animals were fasted 18 h prior to administration
of test compounds. After 6 h of the drug treatment the rats
were sacriﬁced. Stomach was removed and opened along the
greater curvature. Inner lining was washed with normal saline
and examined by magnifying glasses (5·). The number of
ulcers and severity index was calculated using the scores:
0 = no lesions; 1 = superﬁcial ulcers; 2 = deep ulcers;
3 = perforation; 4 = severe perforation.
2.4. Molecular modeling and docking studies
To understand the mechanism of anti-inﬂammatory activity of
the compounds, docking simulation (Morris et al., 1998) was
performed on X-ray crystal structure of COX-2 protein
(PDB code: 3NT1; resolution 1.73 A˚; Duggan et al., 2010)
using Autodock 4.2 (Morris et al., 2009). The protein was pre-
pared by removing B chain, nonreactive water molecules, and
ligand molecules other than crystal ligand (naproxen in COX-
2). The synthesized molecules were built as pdb ﬁles using
PRODRG2 server (Schuttelkopf and van Aalten, 2004).
Gasteiger charges and Kollman united atom charges were
added to the ligand and receptor, respectively. The atomic sol-
vation parameters were assigned using the ADDSOL utility of
Autodock 4.2. The grid calculation was performed using
Autogrid4 program, in which a box dimension of 22.5 A˚ andgrid spacing of 0.375 A˚ parameters were set. The generated
box size allows each member of the tested compound to rotate
freely in order to ﬁnd the conformation with the best binding
free energy. LGA is used as a global optimizer and energy
minimization for docking simulation. Prior to docking the syn-
thesized molecules into target, crystal structure of naproxen
was used to perform control docking to ensure whether the
docking method was valid. The amino acid residues that inter-
act with naproxen produced by the re-docking process were
then compared with amino acid residues that bind the crystal
structure; a root-mean-square deviation (RMSD) that was less
than or equal to 2.0 A˚ was deﬁned as reasonable criteria
(Accelrys-Software-Inc, 2012). The resulted RMSD value
obtained was 0.910 A˚. This indicated that the parameter set
for docking was suitable for reproducing the X-ray structure.
Moreover, the re-docking results for naproxen revealed that
ligand occupies COX-2 receptor-binding pockets and performs
similar intermolecular interaction with surrounding amino
acids.
3. Results and discussion
IR spectroscopic data reveal that synthesized compounds give
characteristic signal at their assigned places. The presence of
ANHACOA linkage between 1655 and 1685 cm1 and NH
stretching between 3350 and 3420 cm1 indicates the synthesis
of the compounds. 1H NMR spectra of all compounds are in
agreement with the suggested structure. Methylene (CH2) pro-
tons of ANHCOCH2CH2A were observed as triplet between
2.3 and 3.4 ppm, which conﬁrms the synthesis of the target
compounds (3a–3n). In case of compound 2, these protons
were deshielded and observed between 2.8 and 4.10 ppm due
to the presence of –Cl. The signals for the benzylic proton were
recorded as singlet between 3.50 and 4.25 ppm, while aromatic
protons were observed between 6.90 and 7.20 ppm as doublet,
with coupling constant (J value) 6–7 Hz. The NH protons
were observed as D2O exchangeable protons.
The pharmacological data imply that 80% of the com-
pounds were found to possess appreciable anti-inﬂammatory
activity as compared to standard drugs, while 13% of com-
pounds hold iota of similar properties (Table 1). Upon critical
introspection of synthesized compounds, it has been found
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methylpiperidine (3g, 72.7%) and substituted piperazine (3l
and 3n, dichlorophenyl, 4-nitrophenypiperazine) exhibited
more protection than standard drugs against carrageenan
induced inﬂammation, while replacement of the dimethyl
groups with diethyl (3b, 63.4%), dipropyl (3c, 66.6%), dipro-
pyl (3e, 60.5%), or 2-methyl-piperidine (3h, 57.3%) reduces
activity. The compounds bearing piperidine, phenyl piperazineTable 1 Acute (carrageenan induced paw edema) and chronic (cotto
compounds.
N
H
R
O
(3a-3n)
Compd. R Mean increase in
paw volume (ml)
(Mean ± SEM)
%
Inhibitiona
3a ANA(CH3)2 0.115 ± 0.020 72.0
3b ANA(CH2CH3)2 0.150 ± 0.030 63.4
3c AN-(CH2CH2CH3)2 0.137 ± 0.037 66.6
3d
N C6H11
CH3
0.150 ± 0.020 63.4
3e ANA(C6H11)2 0.162 ± 0.047 60.5
3f N 0.125 ± 0.025 69.5
3g N 0.112 ± 0.026 72.7
3h
N
0.175 ± 0.025 57.3
3i N N 0.225 ± 0.014 45.1
3j N N 0.129 ± 0.025 68.5
3k N N F 0.130 ± 0.034 68.3
3l
N N
Cl Cl
0.092 ± 0.012 77.6
3m
N
N O
O
C
H2
0.212 ± 0.031 48.3
3n N N NO2 0.075 ± 0.014 81.7
Diclof.
Na
– 0.125 ± 0.014 69.5
Ibuprofen – 0.142 ± 0.025 64.7
Control – 0.402 ± 0.020 –
p values were compared with control group (3 h after inducing edema.) (T
inhibition of carrageenan-induced edema or granuloma between anima
diclofenac sodium (10 mg/kg), Ibuprofen (20 mg/kg) or synthesized comp
a p< 0.05 (signiﬁcant difference). Number of animals (rats) in each grand 4-ﬂuorophenylpiperazine groups exhibited activity similar
to standard drug. Ethyl piperazine derivative (3i, 45.1%) was
least active among all the compounds studied. Data reveal that
compounds studied are capable to reduce the acute inﬂamma-
tion more than the chronic induced by cotton-pellet (Table 1).
The ulcerogenic activity of ibuprofen (60 mg/kg b.wt.) and
compounds (3a, 3l and 3n; 60 mg/kg b.wt.) was performed
according to Cioli et al. (1979). The tested compounds showedn pellet granuloma) anti-inﬂammatory activity of the synthesized
N
O
Cl
Cotton pellets-induced granuloma method a
Weight of moist
cotton Pellet (mg)
(Mean ± SEM)
%
Activitya
Weight of dry
cotton Pellet (mg)
(Mean ± SEM)
%
Activitya
165.25 ± 0.85 31.1 30.33 ± 0.52 48.4
– – – –
– – – –
– – – –
– – – –
– – – –
– – – –
– – – –
– – – –
– – – –
– – – –
152.38 ± 0.90 36.5 35.68 ± 0.85 39.3
– – – –
144.25 ± 1.11 39.9 32.88 ± 0.66 44.0
98.90 ± 0.86 59.0 23.38 ± 0.75 60.2
– – – –
239.38 ± 0.63 – 58.75 ± 0.48 –
ukey’s Test), Anti-inﬂammatory activity was assessed as the percent
ls of control group and animals pretreated with reference drug –
ounds (20 mg/kg, b.wt.).
oup = 4.
Table 2 Ulcerogenic activity of the synthesized compounds in
rats.
Compd. Ulcerogenic activitya
(severity index)b,
(Mean ± SD)
3a (60 mg/kg) 2.20 ± 0.84
3l (60 mg/kg) 2.00 ± 0.71
3n (60 mg/kg) 1.60 ± 0.55
Ibuprofen (60 mg/kg) 2.80 ± 0.45
Control (normal saline) –
a Number of animals in each group = 5.
b p< 0.05 (signiﬁcant difference).
620 A.K. Shakya et al.severity index ranging from 1.60 to 2.20 while the standard
drug ibuprofen exhibited high severity index of 2.80
(Table 2). The ulcerogenic effects of tested compounds were
appreciably lower than the ibuprofen.
In molecular modeling and docking studies, the inter-
molecular interaction between naproxen crystallized with
COX-2 was studied and analyzed. Two critical hydrogen
bonds were created between naproxen and Tyr-355 and Arg-
120 in COX-2 active site (Fig. 1a). In order to simplify the
analysis compounds were used to prepare intermolecular inter-
action with COX-2 (Table 3). The amino acid Arg-120 was
shown to interact with all the synthetic compounds by hydro-
gen bond interaction as shown in Table 3 and Fig. 1b–e.
Compound 3g (Fig. 1b) was found to interact with Arg-120,
Tyr-355 and Ser-530 by hydrogen bond interaction.
Compounds 3i (Fig. 1c) and 3m (Fig. 1d) interact with Arg-
120 & Ser-530 and Arg-120 & Ser-119, respectively. Some
compounds, such as 3e, 3i and 3m do not interact with Tyr-
355, and interestingly they are among the lowest percent
inhibition of COX-2 (Table 3), while compound 3n (Fig. 1e)
has the highest percent inhibition among all the compounds.
In addition to Tyr-355 and Arg-120, compound 3n can interact
with Lys-83 and Ser-471. This will lead to more tight binding;
hence, it showed the highest activity. This may indicate the
importance of hydrogen bond interaction with Arg-120 and
Tyr-355.4. Conclusion
In conclusion, a series of N-(2-(4-chlorobenzyl)-benzo[d]oxa-
zol-5-yl)-3-substituted-propanamide (3a–3n) were synthesized
and evaluated for their anti-inﬂammatory potential. The
experimental data of present study indicate that the synthe-
sized compounds are more effective in acute inﬂammatory
conditions than in chronic one. The tested compounds exhib-
ited less ulcerogenic activity than the reference drug.
Interestingly, the docking results were in agreement with that
of the anti-inﬂammatory activity and against cyclooxygenase
enzyme where the important structural features, spatial
arrangement and binding interaction required for activity were
determined. In vivo studies revealed that compounds 3a, 3l and
3n have signiﬁcant anti-inﬂammatory activities comparable to
standard drugs. Compound 3n (4-nitrophenyl-piperazine
derivative), has interaction with Lys-83 and Ser-471 in addition
to Try-355 and Arg-120 which might be contributing for sig-
niﬁcant activity. Compounds studied in this study have clearly
indicated that the presence of benzo[d]oxazole and substitutedpropanamide moiety has positive impact on anti-inﬂammatory
activities. In conclusion, this series of compound can be
explored more for further development of novel anti-in-
ﬂammatory drugs.
5. Experimental
5.1. Chemistry
5.1.1. 3-chloro-N-(2-(4-chloro-benzyl)-benzo-[d]oxazol-5-yl)-
propionamide (2)
It was prepared by stirring 5-amino-2-(4-chloro benzyl)-
benzo[d]oxazole (1, 10 mM, Yildiz-Oren et al., 2004) dissolved
in dry benzene (20 ml) and chloropropionyl chloride (11 mM)
for 2 h, then the reaction mixture was reﬂuxed for 1 h. After
completion of reaction, the contents were poured on crushed
ice. The precipitated product was collected, washed with 1%
(w/v) potassium carbonate solution and ice cold water, and
dried in vacuum and recrystallized from dichloromethane.
5.1.2. General procedure for synthesis of N-(2-(4-chloro
benzyl)-benzo[d]oxazol-5-yl)-3-substituted-propanamide (3a–
3n)
A mixture of 2 (5 mM) in dry benzene (50 ml) and respective
secondary amine or heterocyclic compounds (10 mM) was
reﬂuxed for 6–8 h. On cooling the amine hydrochloride, which
was crystallized out was ﬁltered and separated. The organic
phase was washed with distilled water to remove the last traces
of hydrochloride and dried on sodium sulfate (exsiccated).
Benzene was removed under reduced pressure. Crude product
was collected and recrystallized using ethanol (90%).
5.1.3. N-(2-(4-chlorobenzyl)-benzo[d]oxazol-5-yl)-3-(di-
methylamino)-propanamide (3a)
Yield 30%, mp 124 C; IR (cm1) (KBr): 3285.62 (NH),
2930.67 (CH), 1685.67 (ACONHA), 1622.25, 1460.30
(C‚C), 1425.30 (ACH), 1152.45 (ArACl), 736.91 (oop). 1H
NMR (300 MHz, CDCl3): d 1.25 (s, 6H, 2· CH3), 2.23–2.26
(t, 2H, J= 9 Hz, ACOCH2), 3.31–3.34 (t, 2H, J= 9 Hz,
ACH2AN), 4.18 (s, 2H, benzylic), 7.40 (d, 2H, J= 6 Hz,
ArAH), 7.58–7.62 (br/m, 2H, ArAH), 7.67–7.70 (d, 1H,
J= 9 Hz, H-7), 8.00–8.05 (m, 2H, H-4, H-6,), 8.13 (s, 1H,
NH). LC-MS-LCQ (ESI, positive mode) for C19H20ClN3O2:
m/z 357.8 [M]+, 358.9 [M + 1]+. Anal. calc for
C19H20ClN3O2; C, 63.77; H, 5.63; N, 11.74; Found C, 63.74;
H, 5.62; N, 11.75.
5.1.4. N-(2-(4-chloro benzyl)-benzo[d]oxazol-5-yl)-3-(diethyl-
amino)propanamide (3b)
Yield: 50%, mp 118 C; IR (cm1, KBr): 3287.9 (NAH),
1664.9 (ACONHA), 2924.5 (ACH), 1622.1, 1483.5
(Aromatic C‚C), 1426.1 (ACHA), 1217.9 (CAN), 1092.3
(ArACl), 1017.1 (CAO), 763.4 (oop). 1H NMR (300 MHz,
CDCl3): d 1.19 (t, 6H, J= 6 Hz, 2· CH3), 2.10 (t, 2H,
J= 3 Hz, ACOACH2A), 2.36–2.41 (q, 4H, J= 3 Hz, 2·
CH2), 2.89 (t, 2H, J= 3 Hz,ACH2AN), 3.49 (s, 2H, benzylic),
7.58 (d, 2H, J= 6 Hz, ArAH), 7.78 (d, 2H, J= 6 Hz, ArAH),
7.92–7.93 (d, 1H, J= 3 Hz, H-7), 8.01–8.09 (m, 2H, H-4, H-
6), 8.26 (s, 1H, NH). Anal. Calc for C21H24ClN3O2; C,
65.36; H, 6.27; N, 10.89; Found C, 65.35; H, 6.28; N, 10.90.
Figure 1 Solid ribbon representation of intermolecular interaction between (a) Naproxen, (b) 3g, (c) 3i, (d) 3m, (e) 3n and COX-2
(PDB = 3NT1) crystal structures. Created by Discovery Studio v3 visualizer (Accelrys-Software-Inc, 2012).
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propyl-amino)propanamide (3c)
Yield 54%, mp 122 C; IR (cm1, KBr): 3356.82 (NAH),
2932.57 (ACH), 1670.67 (ACONHA), 1628.25, 1521.30
(C‚C), 1486.30 (ACH), 1245.43 (CAN), 1050.23 (CAO),
800.91 (oop). 1H NMR (300 MHz, CDCl3): d 0.98 (t, 6H,
J= 3 Hz, 2· CH3) 1.64–1.72 (m/br, 4H, 2· ACH2), 2.48–
2.50 (m, 6H, 3· ACH2,), 2.70 (t, 2H, J= 5 Hz,
ACOACH2
), 3.99 (s, 2H, benzylic), 7.32 (d, 2H, J= 8 Hz,
ArAH), 7.56 (m/br, 2H, ArAH), 7.73–7.81 (d, 1H, J= 8 Hz,
H-7), 7.93–8.03 (m, 2H, H-4, H-6), 8.32 (s, 1H, NH). Anal.Calc for C23H28ClN2O2; C, 66.74; H, 6.82; N, 10.15; Found
C, 66.70; H, 6.80; N, 10.12.
5.1.6. N-(2-(4-chlorobenzyl)-benzo[d]oxazol-5-yl)-3-(N-
cyclo-hexyl-N-methylamino)-propanamide (3d)
Yield 58; mp 140 C; IR (cm1, KBr): 3209.62 (NAH), 2923.88
(ACH Stretching), 1664.45 (ACONHA), 1623.95, 1525.30
(Aromatic C‚C), 1483.15 (ACH bend), 1157.21 (CAN),
1091.63 (CAO), 800.40 (oop). 1H NMR (300 MHz, CDCl3):
d 1.11–1.42 (m/br, 6H, 3· CH2, cy.hex.), 1.72 (m, 4H, 2·
CH2, cy.hex.), 2.18 (s, 3H, CH3), 2.84 (t, 2H, J= 6 Hz,
Table 3 Free energy contribution and Hydrogen bond
interaction for synthetic compounds with COX-2 binding site.
Comp. (DG)
kcal/mol
No. of
bonds
Amino acids contributing in
hydrogen bonding
Naproxen 5.97 2 Arg-120, Tyr-355
3a 9.06 2 Arg-120, Tyr-355
3b 9.65 3 Arg-120, Tyr-355, Ser-530
3c 9.11 3 Arg-120, Tyr-355, Ser-530
3d 10.5 2 Arg-120, Tyr-355
3e 11.67 2 Arg-120, Ser-530
3f 10.09 3 Arg-120, Tyr-355, Ser-530
3g 9.96 3 Arg-120, Tyr-355, Ser-530
3h 10.77 3 Arg-120, Tyr-355, Ser-530
3i 9.05 2 Arg-120, Ser-530
3j 10.90 2 Arg-120, Tyr-355
3k 10.00 2 Arg-120, Tyr-355
3l 9.24 2 Arg-120, Tyr-355
3m 9.99 2 Arg-120, Ser-119
3n 10.93 4 Arg-120, Tyr-355, Ser-471 and
Lys-83
622 A.K. Shakya et al.COACH2), 3.32–3.38 (m, 1H, ACH, cy.hex.), 3.90 (t, 2H,
J= 6 Hz, ACH2AN), 4.23 (s, 2H, benzylic), 7.11 (d, 2H,
J= 7 Hz, ArAH), 7.49–7.54 (m, 2H, ArAH), 7.72 (d, 1H,
J= 6 Hz, H-7), 7.86–7.91 (m, 2H, H-4, H-6), 8.28 (s, 1H,
NH). Anal Calc for C24H28ClN3O2; C, 67.67; H, 6.63; N,
9.87; Found C, 67.61; H, 6.59; N, 9.85.5.1.7. N-(2-(4-chlorobenzyl)-benzo[d]oxazol-5-yl)-3-(dicyclo-
hexylamino)propanamide (3e)
Yield 54%, mp 135 C; IR (cm1, KBr): 3225.62 (NAH),
2965.67 (ACH), 1674.67(ACONHA), 1600.25, 1522.30
(C‚C), 1475.30 (ACH), 1246.48 (CAN), 1092.45 (CACl),
1025.23 (CAO), 746.91 (oop). 1H NMR (300 MHz,
CDCl3): d 0.99–1.35 (m, 12H, 6· CH2, dicy.hex.), 1.67–
1.92 (m, br, 8H, 4· CH2, dicy.hex.), 2.24–2.34 (m, 2H,
J= 6 Hz, ACO ACH2), 2.57 (t, 2H, J= 6 Hz, ACH2),
3.62 (t, 2H, J= 6 Hz, ACH2), 4.15 (s, 2H, benzylic),
7.11(d, 2H, J= 6 Hz, ArAH), 7.59–7.62 (br/m, 2H,
ArAH), 7.73–7.75 (d, 1H, J= 6 Hz, H-7), 7.91–7.95 (m,
2H, H-4, H-6), 8.30 (s, 1H, NH). Anal Calc for
C29H36ClN3O2; C, 70.50; H, 7.34; N, 8.50; Found C,
70.10; H, 7.32; N, 8.40.5.1.8. N-(2-(4-chlorobenzyl)-benzo[d]oxazol-5-yl)-3-
(piperidin-1-yl)propanamide (3f)
Yield 60%, mp 154 C; IR (cm1, KBr): 3266.62 (NAH),
2966.67 (ACH), 1666.67 (ACONH), 1602.25, 1525.30
(C‚C), 1466.30 (ACH bend), 1245.48 (CAN), 1125.23
(CAO), 748.91 (oop). 1H NMR (300 MHz, CDCl3): d 1.66–
1.71 (m, 6H, 3· CH2), 2.34 (m, 4H, 2· CH2), 2.64 (t, 2H,
J= 18 Hz, ACOACH2), 3.69 (t, 2H, J= 3 Hz, ACH2), 4.20
(s, 2H, Abenzylic), 6.67 (d, 2H, J= 6 Hz, ArAH), 6.97 (d,
2H, J= 3 Hz, ArAH), 7.32–7.35 (d, 1H, J= 9 Hz, HA7),
7.65–7.67 (br/m, 2H, H-4, H-6), 8.01 (s, 1H, NH). Anal.
Calc for C22H24ClN3O2; C, 66.14; H, 6.08; N, 10.56; Found
C, 65.97; H, 6.03; N, 10.47.5.1.9. N-(2-(4-chlorobenzyl)-benzo[d]oxazol-5-yl)-3-(4-
methyl-piperidin-1-yl)propanamide (3g)
Yield 60%, mp 162 C; IR (cm1, KBr): 3358.62 (NAH),
3015.25 (ACH), 1684.67 (ACONHA), 1610.25, 1522.30
(C‚C), 1470.20 (ACH), 1278.58 (CAN), 1115.23 (CAO)
756.91 (oop). 1H NMR (300 MHz, CDCl3): d 1.01–1.02 (d,
3H, J= 6 Hz, ACH3), 1.63–1.73 (m, 4H, ACH2, pipd.),
1.98–2.21 (m, 1H, ACH, pipd.), 2.55 (t, 4H, J= 6 Hz,
ACH2A, pipd.), 2.71 (t, 2H, J= 6 Hz, ACOACH2), 3.06 (t,
2H, J= 3 Hz, ACH2A), 4.24 (s, 2H, benzylic), 7.31 (d, 2H,
J= 6 Hz, ArAH), 7.56 (d, 2H, J= 6 Hz, ArAH), 7.68–7.70
(d, 1H, J= 6 Hz, H-7), 7.81–7.83 (m, 2H, H-4, H-6), 8.22 (s,
1H, NH). Anal Calc for C23H26ClN3O2; C, 67.06; H, 6.36;
N, 10.20; Found C, 66.91; H, 6.03; N, 10.11.5.1.10. N-(2-(4-chlorobenzyl)-benzo[d]oxazol-5-yl)-3-(2-
methyl-piperidin-1-yl)propanamide (3h)
Yield 60%, mp 158 C; IR (cm1, KBr): 3356.62 (NAH),
3005.67 (ACH), 1674.67 (ACONHA), 1606.25, 1422.30
(C‚C), 1465.30 (ACH bend), 1248.48 (CAN), 1122.23
(CAO) 766.81 (oop). 1H NMR (300 MHz, CDCl3) d: 1.01–
1.03 (d, 3H, J= 6 Hz, ACH3), 1.48 (br, 2H, pipd.), 2.06–
2.16 (m, 4H, J= 9 Hz, pipd.), 2.56 (t, 2H, J= 6 Hz,
ACOACH2), 2.72 (br/m, 2H, pipd.), 2.82–2.95 (m, br, 1H,
pipd.), 3.08 (t, 2H, J= 6 Hz, ACH2A), 3.90 (s, 2H, benzylic),
7.46 (d, 2H, J= 6 Hz, ArAH), 7.53–7.59 (m, 3H, ArAH, H-
7), 7.63–7.66 (m, 2H, H-4, H-6), 8.01 (s, 1H, NH). Anal Calc
for C23H26ClN3O2; C, 67.06; H, 6.36; N, 10.20; Found C,
66.91; H, 6.03; N, 10.11.5.1.11. N-(2-(4-chlorobenzyl)-benzo[d]oxazol-5-yl)-3-(4-ethyl
piperazin-1-yl)propanamide (3i)
Yield 54%, mp 132 C; IR (cm1, KBr): 3286.2 (NAH), 1668.6
(ACONHA), 2930.5 (ACH), 1624.1, 1527.1 (C‚C), 1483.9
(ACH), 1159.1 (CAN), 1093.1 (CAO) 757.5 (oop). 1H NMR
(300 MHz, CDCl3): d 1.13 (t, 3H, J= 6 Hz, ACH3), 2.48 (t,
2H, J= 12 Hz, ACOACH2), 2.58 (q, 2H, J= 6 Hz,
ANACH2), (m/br, 8H, pipz.), 2.79 (t, 2H, ACH2A), 3.82 (s,
2H, benzylic), 7.57 (d, 2H, J= 6 Hz, ArAH), 7.63 (d, 2H,
J= 6 Hz, ArAH), 7.86–7.88 (d, 1H, J= 6 Hz, H-7), 7.94–
7.96 (m, 2H, H-4, H-6), 8.86 (s, 1H, NH). Anal Calc for
C23H27ClN4O2; C, 63.99; H, 6.10; N, 13.57; Found C, 63.16;
H, 5.89; N, 13.14.5.1.12. N-(2-(4-chlorobenzyl)-benzo[d]oxazol-5-yl)-3-(4-
phenyl piperazin-1-yl)propanamide (3j)
Yield 60%, mp 128 C; IR (cm1, KBr): 3311.62 (NAH),
2955.67 (ACH), 1684.67 (ACONHA), 1615.25, 1520.30
(C‚C), 1445.30 (ACH), 1235.48 (CAN), 1188.23 (CAO)
800.21 (oop). 1H NMR (300 MHz, CDCl3): d 2.09 (t, 2H,
J= 3 Hz, ACOACH2), 2.50 (br/m, 4H, pipz.), 2.78 (t, 2H,
J= 6 Hz, ACH2A), 3.45 (br, 4H, pipz.), 3.90 (s, 2H, benzylic),
6.67 (m, 3H, J= 12 Hz, Hb, Hd, Hf, phenyl pipz.), 6.92 (d, 2H,
J= 7 Hz, ArAH), 7.25 (m, 2H, Hc, He, phenyl pipz.), 7.56 (d,
2H, J= 7 Hz, ArAH), 7.84–7.88 (d, 1H, J= 12 Hz, H-7),
8.08–8.15 (m, 2H, H-4, H-6), 8.46 (s, 1H, NH). Anal calc for
C27H27ClN4O2; C, 68.27; H, 5.73; N, 11.80; Found C, 67.91;
H, 5.17; N, 11.18.
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ﬂuorophenyl)piperazin-1-yl)-propanamide (3k)
Yield 65%, mp 140 C; IR (cm1, KBr): 3355.62 (NAH),
2865.47 (ACH), 1664.67 (ACONHA), 1600.25, 1415.30
(C‚C), 1455.30 (ACH), 1288.48 (CAN), 1178.23 (CAO)
789.11 (oop). 1H NMR (300 MHz, CDCl3): d 2.32 (t, 2H,
J= 6 Hz, ACH2), 2.84 (t, 4H, J= 6 Hz, pipz.), 3.33 (t, 2H,
J= 9 Hz, ACH2A), 3.90 (t, 4H, J= 3 Hz, pipz.), 4.22 (s,
2H, benzylic), 6.61–6.62 (m, 2H, Hb, Hf, ﬂuoroph.), 6.84–
6.89 (br, 2H, Hc, He, ﬂuoroph.), 7.11 (d, 2H, J= 6 Hz,
ArAH), 7.49 (d, 2H, J= 7 Hz, ArAH), 7.62–7.65 (d, 1H,
J= 9 Hz, H-7), 7.86–7.95 (m, 2H, H-4, H-6), 8.28 (s, 1H,
NH). Anal cal for C27H26ClFN4O2; C, 65.78; H, 5.32; N,
11.37; Found C, 65.73; H, 5.31; N, 11.35.5.1.14. N-(2-(4-chlorobenzyl)-benzo[d]oxazol-5-yl)-3-(4-(2,3-
dichlorophenyl)piperazin-1-yl)-propanamide (3l)
Yield 70%, mp 152 C; IR (cm1, KBr): 3355.22 (NAH),
2955.67 (ACH), 1660.67 (ACONHA), 1636.25, 1422.30
(C‚C), 1415.40 (ACH), 1295.48 (CAN), 1000.23 (CAO)
799.91 (oop). 1H NMR (300 MHz, CDCl3): d 2.12 (t, 2H,
J= 6 Hz, ACOACH2A), 2.43 (t, 4H, J= 6.0 Hz, pipz.),
2.99 (t, 2H, J= 6.0 Hz, ACOACH2A), 3.28 (t, 4H,
J= 3.0 Hz, pipz.), 3.72 (s, 2H, benzylic), 6.88(d, 1H,
J= 3.0 Hz, Hf,), 7.10 (d, 1H, J= 6.0 Hz, Hd), 7.42 (m, 1H,
He), 7.60 (d, 2H, J= 3 Hz, ArAH), 7.69 (d, 2H, J= 6 Hz,
ArAH), 7.73(d, 1H, J= 3 Hz, H-7), 8.01–8.03 (br/m, 2H, H-
4, H-6), 8.14 (s, 1H, NH). Anal calc for C27H25Cl3N4O2; C,
59.63; H, 4.63; N, 10.30; Found C, 59.58; H, 4.59; N, 10.01.5.1.15. N-(2-(4-chlorobenzyl)-benzo[d]oxazol-5-yl)-3-(4-
((benzo[d][1,3]dioxol-6-yl)-methyl)-piperazin-1-yl)-
propanamide (3m)
Yield 60%, mp 150 C; IR (cm1, KBr): 3226.62 (NAH),
3000.67 (ACH), 1670.67 (ACONHA), 1610.25, 1422.30
(C‚C), 1458.30 (ACH), 1310.48 (CAN), 1100.23 (CAO)
745.91 (oop). 1H NMR (300 MHz, CDCl3): d 2.18 (t, 2H,
J= 3 Hz, ACOACH2), 2.60–2.75 (br, 8H, pipz.), 2.84 (t,
2H, J= 6 Hz, ACH2A), 3.90 (s, 2H, benzylic), 4.18 (s, 2H,
benzylic), 5.80 (s, 2H, Hb), 6.31 (s, 1H, Hd), 6.45 (dd, 2H,
Hg, Hf), 7.27–7.39 (m, 3H, ArAH, H-7), 7.69–7.77 (m, 4H,
Ar-H, H-4, H-6), 7.90 (s, 1H, NH). Anal calc for
C29H29ClN4O4; C, 65.35; H, 5.48; N, 10.51; found C, 65.19;
H, 5.40; N, 10.49.
5.1.16. N-(2(4-chloro-benzyl)-benzo[d]oxazol-5-yl)-3-(4-(4-
nitrophenyl)-piperazin-1-yl)propanamide (3n)
Yield 65%, mp 148 C; IR (cm1, KBr): 3402.62 (NAH),
2850.67 (ACH), 1664.67 (ACONHA), 1600.25, 1424.30
(C‚C), 1466.30 (ACH bend), 1262.48 (CAN), 1145.23
(CAO) 765.91 (oop). 1H NMR (300 MHz, CDCl3): d 2.38 (t,
2H, J= 3 Hz, ACOACH2), 2.79 (t, 4H, J= 3 Hz, pipz.),
3.02 (t, 2H, J= 6 Hz, ACH2), 3.90 (t, 4H, J= 6 Hz, pipz.),
4.20 (s, 2H, benzylic), 6.48–6.51 (m, 2H, Hb, Hf), 6.77 (d,
2H, J= 6 Hz, ArAH), 7.38 (d, 2H, J= 6 Hz, ArAH), 7.46–
7.62 (m, 3H, H-4, H-6, H-7), 7.88–7.91 (t, 2H, J= 9 Hz,
Hc, He, ArAH), 8.28 (s, 1H, NH). LC-MS-LCQ (ESI, positive
mode) 521.0 [M + 1]+. Anal. calc. for C27H26ClN5O4; C,
62.37; H, 5.04; N, 13.47; found C, 62.35; H, 5.04; N, 13.48.5.2. Statistical analysis
Experimental data are expressed as mean. Statistical difference
between the treated and the control groups was evaluated by
one way analysis of variance (AVOVA) followed by the
Tukey’s test as a post-ANOVA (GraphPad Prism 5, San
Diego, CA, USA) to determine the statistical signiﬁcance. A
P value <0.05 was considered statistically signiﬁcant.
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